Klin Farmakol Farm. 2022;36(3):93-100 | DOI: 10.36290/far.2022.015

Is pharmacological eradication of HIV possible?

Svatava Snopková1, Petr Husa1, Šárka Kozáková2
1 Klinika infekčních chorob FN Brno a LF MU Brno
2 Ústavní lékárna FN Brno

The rapid onset of the global HIV pandemic at the turn of the 1980s and 1990s made the disease one of the most studied infectious diseases in the history of medicine. This was also reflected in the rapid development of effective antiretroviral drugs. Antiretroviral therapy has been in clinical practice since 1996. Treatment has significantly prolonged and improved the lives of people living with HIV, saving and still rescuing millions of people infected worldwide. However, after more than twenty years, it is evident that the treatment provided with the current pharmacotherapy is not entirely optimal and has its limits. Its potential is only suppressive, not eradicating. A specific feature of HIV is its ability to integrate its genome in the form of proviral DNA into the genome of the host cell. These cells do not induce the expression of viral antigens on their surface, the viral agent is not recognized by the immune system and is completely untouchable by antiretrovirals. The reservoir of latently infected cells consists of multiple cell types and tissue compartments, which become a barrier to effective treatment and possible eradication of HIV. Two basic directions of development of therapeutic intervention were defined - sterilization and functional. The ideal goal of sterilization treatment is to achieve the elimi­nation of active and latent viral agents from the human body. The goal of functional treatment is to induce long-term remission as a result of a strong host defense response mediated by immune mechanisms, even though the competent viral agent remains in the body. The text deals with the main areas of current research into new drugs and new treatment principles: long-acting slow-release antiretrovirals, immunotherapy, cell and gene therapy, shock and kill strategies, and block and lock strategies.

Keywords: HIV, antiretroviral therapy, HIV eradication, immunotherapy, neutralizing antibodies.

Accepted: November 3, 2022; Published: November 3, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Snopková S, Husa P, Kozáková Š. Is pharmacological eradication of HIV possible? Klin Farmakol Farm. 2022;36(3):93-100. doi: 10.36290/far.2022.015.
Download citation

References

  1. Peterson TA, MacLean AG. Current and future therapeutic strategies for lentiviral eradication from macrophage reservoirs. Neuroimmune Pharmacol. 2019;14(1):68-93. Go to original source... Go to PubMed...
  2. Margolis DM, Koup RA, Ferrari G. HIV antibodies for treatment of HIV infection. Immunol Rev. 2017;275(1):313-323. Go to original source... Go to PubMed...
  3. Thoueille P, Choong E, Cavassini M, et al. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022;77(2):290-302. Go to original source... Go to PubMed...
  4. Snopková S, Rozsypal H, Aster V, et al. Doporučený postup péče o dospělé infikované HIV a postexpoziční profylaxe infekce HIV. Klin mikrobiol inf lék. 2019;3:96-119.
  5. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV [Internet]. Januar 20, 2022. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). [cited 2022 Feb 10]; Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines.
  6. Snopková S, Husa P. Moderní léčba HIV. PROFI Medicína. 2021;13-14:16-22.
  7. Henderson LJ, Reoma LB, Kovacs JA, et al. Advances toward curing HIV-1 infection in tissue reservoirs. J Virol [Internet]. 2020; 94:e00375-19 [cited 2022 Feb 15]. Available from: https://doi.org/10.1128/JVI.00375-19. Go to original source... Go to PubMed...
  8. Cao S, Woodrow KA. Nanotechnology approaches to eradicating HIV reservoirs. Eur J Pharm Biopharm. 2019;138:48-63. Go to original source... Go to PubMed...
  9. Lu DY, Wu HY, Yarla NS, et al. HAART in HIV/AIDS treatment: future trends. Infect Disord Drug Targets. 2018;18(1):15-22. Go to original source... Go to PubMed...
  10. Paiardini M, Dhodapkar K, Harper J, et al. Editorial: HIV and cancer immunotherapy: similar challenges and converging approaches. Front Immunol [Internet]. 2020;11:519 [cited 2022 Feb 15]. Available from: DOI: 10.3389/fimmu.2020.00519. Go to original source... Go to PubMed...
  11. Kirtane AR, Langer R, Traverso G. Past, present, and future drug delivery systems for antiretrovirals. J Pharm Sci. 2016;105(12):3471-3482. Go to original source... Go to PubMed...
  12. Alrubayyi A, Ogbe A, Moreno Cubero E, et al. Harnessing natural killer cell innate and adaptive traits in HIV infection. Front Cell Infect Microbiol [Internet]. 2020;10:395 [cited 2022 Feb 10]. Available from: DOI: 10.3389/fcimb.2020.00395. Go to original source... Go to PubMed...
  13. Liu R, Simonetti FR, Ho YC. The forces driving clonal expansion of the HIV-1 latent reservoir. Virol J [Internet]. 2020;17:4 [cited 2022 Feb 10]. Available from: https://doi.org/10.1186/s12985-019-1276-8. Go to original source... Go to PubMed...
  14. Hong FF, Mellors JW. Changes in HIV reservoirs during long-term antiretroviral therapy. Curr Opin HIV AIDS. 2015;10(1):43-48. Go to original source... Go to PubMed...
  15. Margolis DM, Archin NM, Cohen MS, et al. Curing HIV: seeking to target and clear persistent infection. Cell. 2020;181(1):189-206. Go to original source... Go to PubMed...
  16. Trivedi J, Mahajan D, Jaffe RJ, et al. Recent advances in the development of integrase inhibitors for HIV treatment. Curr HIV/AIDS Rep. 2020;17(1):63-75. Go to original source... Go to PubMed...
  17. Perreau M, Banga R, Pantaleo G. Target immune interventions for an HIV-1 cure. Trends Mol Med [Internet]. 2017;23(10) [cited 2022 Feb 10]. Available from: http://dx.doi.org/10.1016/j.molmed.2017.08.006. Go to original source... Go to PubMed...
  18. Vieillard V, Gharakhanian S, Lucar O, et al. Perspectives for immunotherapy: which applications might achieve an HIV functional cure? Oncotarget. 2016;7(25):38946-38958. Go to original source... Go to PubMed...
  19. Ahlenstiel CL, Symonds G, Kent SJ, et al. Block and lock HIV cure strategies to control the latent reservoir. Front Cell Infect Microbiol [Internet]. 2020;10:424 [cited 2022 Feb 10]. Available from: https://doi.org/10.3389/fcimb.2020.00424. Go to original source... Go to PubMed...
  20. Ait-Ammar A, Kula A, Darcis G, et al. Current status of latency reversing agents facing the heterogenity of HIV-1 cellular and tissue reservoirs. Front Microbiol [Internet]. 2020;10:3060 [cited 2022 Feb 10]. Available from: DOI: 10.3389/fmicb.2019.03060. Go to original source... Go to PubMed...
  21. Grau-Expo´sito J, Luque-Ballesteros L, Navarro J, et al. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. PLoS Pathog [Internet]. 2019;15(8): e1007991 [cited 2022 Feb 10]. Available from: https://doi.org/10.1371/journal.ppat.1007991 E. Go to original source... Go to PubMed...
  22. Bowen A, Sweeney EE, Fernandes R. Nanoparticle-based immunoengineered approaches for combating HIV. Front Immunol [Internet]. 2020;11:789 [cited 2022 Jan 12]. Available from: DOI: 10.3389/fimmu.2020.00789. Go to original source... Go to PubMed...
  23. Oti VB. Nanoparticles and its implications in HIV/AIDS therapy. Curr Drug Discov Technol. 2020;17(4):448-456. Go to original source... Go to PubMed...
  24. Patil V, Patel A. Biodegradable nanoparticles: a recent approach and applications. Current Drug Targets. 2020; 21(16):1722-1732. Go to original source... Go to PubMed...
  25. Kevadiya BD, Ottemann B, Mukadam IZ, et al. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics. 2020;10(2):630-656. Go to original source... Go to PubMed...
  26. Edagwa B, McMillan JE, Sillman B, et al. Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv. 2017;14(11):1281-191. Go to original source... Go to PubMed...
  27. Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, et al. Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf. 2017;16(8):923-932. Go to original source... Go to PubMed...
  28. Flexner C, Owen A, Siccardi M, et al. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents [Internet]. 2021;57(1):106220 [cited 2022 Jan 12]. Available from: DOI: 10.1016/j.ijantimicag.2020.106220. Go to original source... Go to PubMed...
  29. Cambou MC, Landovitz RJ. Novel antiretroviral agents. Curr HIV/AIDS Rep. 2020;17:118-124. Go to original source... Go to PubMed...
  30. Schurmann D, Rudd DJ, Zhang S, et al. Lancet HIV [Internet]. 2020;7(3):e164-e172 [cited 2022 Jan 12]. Available from: DOI: 10.1016/S2352-3018(19)30372-8. Go to original source... Go to PubMed...
  31. Home - ClinicalTrials.gov [cited 2022 Jan 12]. The United States National Library of Medicine at the National Institutes of Health. Available from: www.clinicaltrials.gov.
  32. Highleyman L. Trials of long-acting islatravir for HIV treat­ment and prevention placed on hold. In: Aidsmap.com [Internet]. 2021 Dec 21. [cited 2022 Jan 12]. Available from: https://www.aidsmap.com/news/dec-2021/trials-long-acting-islatravir-hiv-treatment-and-prevention-placed-hold.
  33. Margot N, Ram R, Rhee M, et al. Absence of lenacapavir (GS-6207) phenotypic resistance in HIV Gag cleavage site mutants and in isolates with resistance to existing drug classes. Antimicrob Agents Chemother [Internet]. 2021;65:e02057-20 [cited 2022 Jan 12]. Available from: https://doi.org/10.1128/AAC.02057-20. Go to original source... Go to PubMed...
  34. Dvory-Sobol H, Shaik N, Callebaut C, et al. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022;17(1):15-21. Go to original source... Go to PubMed...
  35. Menéndez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022;43(1):16-29. Go to original source... Go to PubMed...
  36. Terry M. FDA places hold on Gilead HIV trials over vial quality concerns. In: BioSpace.com [Internet]. 2021 Dec 22. [cited 2022 Jan 12]. Availble from: https://www.biospace.com/article/fda-places-clinical-hold-on-use-of-glass-vials-in-gilead-s-hiv-trials/.
  37. Barin F, Stefic K. Anticorps neutralisants tri-spécifiques. Une solution pour l'immunoprophylaxie ou l'immunothérapie anti-VIH ? Med Sci. 2018;34:109-128. Go to original source... Go to PubMed...
  38. Wang Q, Zhang L. Broadly neutralizing antibodies and vaccine design against HIV-1 infection. Front Med. 2020;14(1):30-42. Go to original source... Go to PubMed...
  39. Haynes BF, Burtzon DR, Mascola JR. Multiple roles for HIV brodly neutralizing antibodies. Sci Transl Med [Internet]. 2019;11:516.eaaz2686 [cited 2022 Jan 12]. Available from: DOI: 10.1126/scitranslmed.aaz2686. Go to original source... Go to PubMed...
  40. Liu Y, Cao W, Sun M, et al. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg Microbes Infect. 2020;9(1):194-206. Go to original source... Go to PubMed...
  41. Bradley T, Peppa D, Pedroza-Pacheco I, et al. RAB11FIP5 expression and altered natural killer cell function are associated with induction of HIV broadly neutralizing antibody responses. Cell. 2018;175:387-399. Go to original source... Go to PubMed...
  42. Dufloo J, Planchais C, Frémont S, et al. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. Nat Commun [Internet]. 2022;13(1):630 [cited 2022 Jan 12]. Available from: DOI: 10.1038/s41467-022-28307-7. Go to original source... Go to PubMed...
  43. Beccari MV, Mogle BT, Sidman EF, et al. Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection. Antimicrob Agents Chemother [Internet]. 2019; 63:e00110-19 [cited 2022 Jan 12]. Available from: https://doi.org/10.1128/AAC.00110-19. Go to original source... Go to PubMed...
  44. Wesley D. Kufel. Antibody-based strategies in HIV therapy. Int J Antimicrob Agents [Internet]. 2020;56(6):106186 [cited 2022 Jan 25]. Available from: DOI: 10.1016/j.ijantimicag.2020.106186. Go to original source... Go to PubMed...
  45. Ahmad A, Rinaldo CR. A novel anti-HIV immunotherapy to cure HIV. AIDS. 2017;31(3):447-449. Go to original source... Go to PubMed...
  46. Vansant G, Bruggemans A, Janssens J, et al. Block-and-lock strategies to cure hiv infection. Viruses [Internet]. 2020;12(1):84 [cited 2022 Jan 25]. Available from: DOI: 10.3390/v12010084. Go to original source... Go to PubMed...
  47. Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019;568:244-248. Go to original source... Go to PubMed...
  48. Dash PK, Kaminski R, Bella R, et al. Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. Nat Commun [Internet]. 2019;10(1):2753 [cited 2022 Jan 25]. Available from: DOI: 10.1038/s41467-019-10366-y. Go to original source... Go to PubMed...
  49. Ahlenstiel CL, Symonds G, Kent SJ, et al. Block and lock HIV cure strategies to control the latent reservoir. Front Cell Infect Microbiol [Internet]. 2020;10:424 [cited 2022 Jan 25]. Available from: DOI: 10.3389/fcimb.2020.00424. Go to original source... Go to PubMed...
  50. Dash PK, Kaminski R, Bellaet R, et al. Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. Nat Commun [Internet]. 2019;10(1):2753 [cited 2022 Jan 25]. Available from: DOI: 10.1038/s41467-019-10366-y. Go to original source... Go to PubMed...
  51. Palermo E, Acchioni C, Di Carlo D, et al. Activation of latent HIV-1 T cell reservoir with a combination of innate immune and epigenetic regulators. J Virol [Internet]. 2019;93:e01194-19 [cited 2022 Jan 25]. Available from: DOI: 10.1128/JVI.01194-19. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.